Strategies for intervention with chemopreventive agents

✍ Scribed by Martin Lipkin

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: French
• Weight: 392 KB
• Volume: 69
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19960220)69:1<64::aid-ijc17>3.0.co;2-k

✦ Synopsis

Different mechanisms of activity have led to the development of a wide variety of intermediate biomarkers to measure the efficacy of chemopreventive agents. Chemopreventive agents are now being used in pre-clinical models that have targeted mutations or normal cells. Based on pre-clinical findings, clinical chemoprevention studies have progressed to measure the possible modulation of dysplastic lesions, including adenomas. Human studies are best carried out where the study design matches the known activity of the agents on cells in early, midor late stages of abnormal cellular development, previously determined in pre-clinical studies. o 1996 Wiley-Liss, Inc.

The many stages of abnormal cellular development prior to neoplasia lead to the application of widely differing chemopreventive approaches. These different approaches and mechanisms (e.g., Wattenberg et aL, 1992;Lipkin, 1988) have resulted in widely differing assays to measure the activities of chemopreventive agents.

Principles that have guided the development of assay systems now used in chemoprevention studies include the following